Lumicell

Lumicell

MA - Newton
Biotechnology
WebsiteLinkedInCareers Page

Focus: Cancer imaging device technology

Lumicell is a life sciences company focused on Cancer imaging device technology.

Oncology
Open Jobs
3

Products & Portfolio (1)

LUMISIGHT
pegulicianine
Growth
INTRAVENOUS ยท POWDER
12.1 Mechanism of Action Pegulicianine is a prodrug that is optically inactive when intact and produces a fluorescent signal after its peptide chain is cleaved by cathepsins and matrix metalloproteases (MMPs). The levels of these enzymes are higher in and around tumor and tumor-associated cells than normal cells. This enzymatic cleavage results in "fragment 2" and "fragment 3", which are optically active metabolites that emit fluorescence, as well as "fragment 1" containing the fluorescence quencher that keeps the intact molecule optically inactive. "Fragment 2" and "fragment 3" absorb light in the visible light region with a peak absorption at 650 nm and fluoresce with a peak emission at 675 nm. 12.2 Pharmacodynamics The relationships between the plasma concentrations of the optically active metabolites and the time course of pharmacodynamic response have not been fully characterized. 12.3 Pharmacokinetics Elimination Metabolism Pegulicianine is cleaved by cathepsins and matrix metalloproteases to the active metabolites "fragment 2" and "fragment 3." Pegulicianine undergoes minimal hepatic metabolism in vitro. Excretion Pegulicianine excretion pathway in humans is unknown. Observed blue/green discoloration of urine (chromaturia) in subjects receiving pegulicianine suggests that pegulicianine and/or its metabolites may be excreted renally. Specific Populations Patients with Renal Impairment Mild renal impairment (RI) does not appear to have a clinically meaningful effect on the pharmacokinetics, safety, and efficacy of pegulicianine and fragment 3; fragment 2 data are not available. The effect of moderate or severe RI on the pharmacokinetics, safety, and efficacy of pegulicianine, fragment 2, and fragment 3 has not been evaluated.
breast cancer
2024
0

Pipeline & Clinical Trials

LUM Imaging System
Low Grade Glioma of Brain
N/A
Clinical Trials (1)
NCT03717142Feasibility of the LUM Imaging System for Detection of Cancer to the Brain
N/A
LUM Imaging System
Pancreatic Cancer
N/A
Clinical Trials (1)
NCT04276909Feasibility Study of LUM Imaging System for Pancreatic Cancer
N/A
Phase 1/2
Clinical Trials (1)
NCT02584244Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
Phase 1/2
LUM Imaging System
Prostate Cancer
Phase 1/2
Clinical Trials (1)
NCT03441464Feasibility of the LUM Imaging System for Detection of Prostate Cancer
Phase 1/2
LUM Imaging System
Peritoneal Metastases
Phase 1/2
Clinical Trials (1)
NCT03834272Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT02438358Feasibility Study of Intraoperative Imaging in Breast Cancer
Phase 1/2
Phase 2
Clinical Trials (1)
NCT04440982Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients
Phase 2
LUM Imaging System
Breast Cancer
Phase 2
Clinical Trials (1)
NCT03321929Intraoperative Detection of Residual Cancer in Breast Cancer
Phase 2
Study Device Arm
Breast Cancer
Phase 3
Clinical Trials (1)
NCT03686215Investigation of Novel Surgical Imaging for Tumor Excision
Phase 3

Open Jobs (3)

Senior Director of Quality

Waltham, Massachusetts
Quality Assurance
3h ago

Account Executive - Midwest

Commercial
2w ago

Senior Quality Engineer

Waltham, Massachusetts
Quality Assurance
2w ago
Interview Prep Quick Facts
Founded: 2024
Portfolio: 1 approved product, 9 clinical trials
Top TAs: Oncology
Open Roles: 3 active jobs
Portfolio Health
Growth1 (100%)
1 total products
Therapeutic Area Focus
Oncology
1 marketed9 pipeline
Marketed
Pipeline

Hiring Trend

Stable
3
Open Roles
+1
Added
-3
Filled/Removed

Based on last 4 crawl cycles